ABOUT LIFE SCIENCE LEADER
Life Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform readers of industry best practices and motivate them to implement those practices in their businesses. Life Science Leader features interviews with executives from the leading pharma and biotech companies, including Pfizer, Merck, Bayer, GSK, Novo Nordisk, Daiichi Sankyo, Eli Lilly, and Janssen, as well as the FDA and small, up-and-coming biotech developers. This exclusive thought leadership provides an in-depth look into industry trends and hot topics that will impact the growth of the pharmaceutical and biotech markets. As the market is continually growing and innovating, these insights provide readers with actionable information and strategies to implement when navigating the evolving clinical, manufacturing, entrepreneurial, and regulatory landscapes.
All article pitches should be sent to Ben Comer, Chief Editor.
Life Science Connect Mission
To connect the people, ideas, and organizations needed to advance the development of pharmaceuticals, biologics, diagnostics, and medical devices that improve the human condition so that they can be brought to market in a safe and cost-effective manner.
IN THIS MONTH'S ISSUE
- Gene Editing Versus Gene Therapy: Is There A Difference?
- The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
- Ensuring Diversity And Accessibility In Neurological Research
- A New Year's Resolution Suggestion For The FDA
- Pharma's Customer Engagement Evolution: Is Your Data Governance Keeping Pace?
- 2023 ADC Roundup: A Year Of Collaboration And Licensing Deals
- Five Financial Strategies Life Sciences Companies Should Consider
- Evolving Business Models: Pharmaceutical Incubators
- An Uncertain Future For Interchangeability
- Life Sciences M&A Outlook: Challenges And Opportunities In 2024
- Biopharma's Eminent Challenges In 2024 — Inside & Out
- Defining A Competitive Next-Gen RNA Therapeutic In 2024
- Accelerating Drug Development With Real World Data
- Top 2024 Clinical Trial Site Challenges: Staffing & Technology